1. Structurally convergent antibodies derived from different vaccine strategies target the influenza virus HA anchor epitope with a subset of V H 3 and V K 3 genes.
- Author
-
Lin TH, Lee CD, Fernández-Quintero ML, Ferguson JA, Han J, Zhu X, Yu W, Guthmiller JJ, Krammer F, Wilson PC, Ward AB, and Wilson IA
- Subjects
- Humans, Influenza, Human immunology, Influenza, Human prevention & control, Influenza, Human virology, Animals, Influenza Vaccines immunology, Epitopes immunology, Epitopes chemistry, Hemagglutinin Glycoproteins, Influenza Virus immunology, Hemagglutinin Glycoproteins, Influenza Virus chemistry, Hemagglutinin Glycoproteins, Influenza Virus genetics, Influenza A Virus, H1N1 Subtype immunology, Influenza A Virus, H1N1 Subtype genetics, Antibodies, Viral immunology, Antibodies, Neutralizing immunology
- Abstract
H1N1 influenza viruses are responsible for both seasonal and pandemic influenza. The continual antigenic shift and drift of these viruses highlight the urgent need for a universal influenza vaccine to elicit broadly neutralizing antibodies (bnAbs). Identification and characterization of bnAbs elicited in natural infection and immunization to influenza virus hemagglutinin (HA) can provide insights for development of a universal influenza vaccine. Here, we structurally and biophysically characterize four antibodies that bind to a conserved region on the HA membrane-proximal region known as the anchor epitope. Despite some diversity in their V
H and VK genes, the antibodies interact with the HA through germline-encoded residues in HCDR2 and LCDR3. Somatic mutations on HCDR3 also contribute hydrophobic interactions with the conserved HA epitope. This convergent binding mode provides extensive neutralization breadth against H1N1 viruses and suggests possible countermeasures against H1N1 viruses., Competing Interests: Competing interests: The authors declare the following competing interests. Florian Krammer is listed as a co-inventor on patent applications filed by The Icahn School of Medicine at Mount Sinai relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines, and influenza virus therapeutics. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. Florian Krammer is a co-founder and scientific advisory board member of Castlevax. Florian Krammer has consulted for Merck, CureVac, Seqirus, GSK, and Pfizer and is currently consulting for 3rd Rock Ventures, Sanofi, Gritstone and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development. Patrick Wilson and Jenna Guthmiller are listed as co-inventors on a patent application filed by the University of Chicago relating to anchor epitope targeting antibodies. The remaining Authors have no competing interests to declare., (© 2025. The Author(s).)- Published
- 2025
- Full Text
- View/download PDF